Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02367846 · ClinicalTrials.gov registry record · Phase 4
Assessing the Impact of Contraceptives on Bone Health Using 41Ca
A Phase 4 study of Other Disorders of Bone Development and Growth, sponsored by Penn State University.
- Active
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT02367846: Active Phase 4 study of Other Disorders of Bone Development and Growth, sponsored by Penn State University.
NCT02367846 is a Phase 4 study of Other Disorders of Bone Development and Growth that is active but no longer recruiting, run by Penn State University. The registered enrollment target is 6 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02367846, a Phase 4 study of Other Disorders of Bone Development and Growth, is active but no longer recruiting, sponsored by Penn State University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This preclinical randomized crossover study will examine the effects of oral versus non-oral contraceptive therapy on bone turnover in young exercising women. In an effort to expose the route-dependent effects of oral versus non-oral contraceptive therapy on bone turnover, the investigators will examine 1) the effects of ethinyl estradiol on bone calcium balance using the 41Ca technology and 2) the underlying physiological mechanisms associated with the effects of oral versus non-oral contraceptive therapy on net bone calcium balance.
Primary Outcome
Changes in the 41Ca:Ca ratio in 24-h urine samples measured every 10-14 days during and after oral and non-oral contraceptive therapy as determined by Accelerometer Mass Spectrometry
Conditions Studied
Interventions
- DRUG Combined Oral Contraceptive (COC)
- DRUG Contraceptive Vaginal Ring (CVR)
Study Locations (1)
Pennsylvania
- Women's Health and Exercise Laboratories, The Pennsylvania State University - University Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
What the registry record for NCT02367846 still lists
NCT02367846 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Other Disorders of Bone Development and Growth appearing as the primary indexed condition, and to 2 interventions - of which Combined Oral Contraceptive (COC) is the first listed.
NCT02367846 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02367846 about?
NCT02367846 is a clinical study titled "Assessing the Impact of Contraceptives on Bone Health Using 41Ca". This preclinical randomized crossover study will examine the effects of oral versus non-oral contraceptive therapy on bone turnover in young exercising women. In an effort to expose the route-dependent effects of oral versus non-oral contraceptive therapy on bone turnover, the investigators will exa...
What is the current status of trial NCT02367846?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2015-01. Estimated completion is 2026-12.
What conditions does trial NCT02367846 study?
This clinical trial studies the following conditions: Other Disorders of Bone Development and Growth.
What interventions are being tested in trial NCT02367846?
The interventions under investigation include: Combined Oral Contraceptive (COC) (DRUG), Contraceptive Vaginal Ring (CVR) (DRUG).
Who is sponsoring clinical trial NCT02367846?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02367846 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02367846's enrollment target sits among peer trials
6 1984th of 2000 higher than 12 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia